Evolent reported $725 million of quarterly revenue and $34.3 million of adjusted EBITDA, up approximately 22% sequentially, while raising full-year adjusted EBITDA guidance to $130 million to $135 million and reiterating revenue guidance of $2.6 billion to $2.7 billion.
EVH · Evolent Health, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 68%
- Last earnings
- Nov 5, 2026
- Latest filing
- 10-Q · Nov 5
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Evolent Health reported September 30, 2026 quarter revenue of 725,367 thousand dollars and adjusted EBITDA of 34,257 thousand dollars. It raised 2026 adjusted EBITDA guidance to $130.0 million to $135.0 million and reiterated $2.6 billion to $2.7 billion revenue guidance.
Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Q3 delivered sequential revenue and adjusted EBITDA growth, better MER, raised full-year adjusted EBITDA guidance, customer expansions, AI-driven efficiency, and a 2027 outlook of at least $150 million at the adjusted EBITDA guidance midpoint. Risks include year-over-year margin deterioration, lower specialty revenue, a smaller Q4 MER benefit, $776 million of net debt, constrained cash flow, and 2027 attrition, scope-adjustment, and investment headwinds.
- + Management retained confidence that the midpoint of 2027 adjusted EBITDA guidance will be $150 million or higher.
- + Evolent plans to deploy up to $50 million toward reducing debt by year-end while preserving financial flexibility.
- − Specialty technology and services revenue declined approximately 7% sequentially to $73 million.
- − Management expects a smaller sequential MER improvement in Q4 because part of the anticipated benefit was realized in Q3.
- − Membership attrition, contract scope adjustments, and targeted investments are expected to offset 2027 earnings tailwinds.
- − Full-year operating cash flow remains constrained by annual cash interest and the timing of reconciliation payments.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | 84.37M | nine months ended September 30, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 4.5% | nine months ended September 30, 2026 | — |
| Adjusted income attributable to common shareholders non-GAAP | 7.27M | nine months ended September 30, 2026 | — |
| Adjusted income per share attributable to common shareholders non-GAAP | $0.06 | nine months ended September 30, 2026 | — |
| Average Lives on Platform/Cases - Administrative Services | 1.16M | three months ended September 30, 2026 | — |
|
|
|||
| Average Lives on Platform/Cases - Performance Suite | 7.2M | three months ended September 30, 2026 | — |
|
|
|||
| Average Lives on Platform/Cases - Specialty Technology and Services Suite | 74.73M | three months ended September 30, 2026 | — |
|
|
|||
| Average PMPM Fees/ Revenue per Case - Administrative Services | $13.84 | three months ended September 30, 2026 | — |
|
|
|||
| Average PMPM Fees/ Revenue per Case - Cases | $3,605 | three months ended September 30, 2026 | — |
|
|
|||
| Average PMPM Fees/ Revenue per Case - Performance Suite | $26.14 | three months ended September 30, 2026 | — |
|
|
|||
| Average PMPM Fees/ Revenue per Case - Specialty Technology and Services Suite | $0.32 | three months ended September 30, 2026 | — |
|
|
|||
| Average Unique Members | 39.8M | three months ended September 30, 2026 | — |
|
|
|||
| Cases | 11K | three months ended September 30, 2026 | — |
|
|
|||
| Medical expense ratio | 93.9% | nine months ended September 30, 2026 | — |
|
|
|||
| Medical Expense Ratio excluding Evolent Care Partners non-GAAP | 95.3% | Q2 2026 | — |
| Performance Suite revenue excluding revenue from Evolent Care Partners non-GAAP | $484.5M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EVH
this stock
Evolent Health, Inc.
|
$441.11M | -2.5% | -1.8% | — | 9.4% |
|
VEEV
Veeva Systems Inc
|
$43.10B | +19.3% | +28.1% | 43.6 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.50B | +67.8% | +28.2% | 34.2 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$9.86B | -8.5% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 12
Evolent Health reported revenue of $725.4 million for the three months ended September 30, 2026, up 51.3%, compared to 2025. Nine-month revenue rose 33.2% to $1.9 billion, while operating losses widened in both periods.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EVH | -20.4% | -18.8% | -1.5% | -9.3% | -2.5% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -11.9% | -9.5% | +7.7% | -0.6% | -3.7% |